5498 results about "Micro particles" patented technology

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful election of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

The present invention provides methods for determining a nucleic acid sequence by performing successive cycles of duplex extension along a single stranded template. The cycles comprise steps of extension, ligation, and, preferably, cleavage. In certain embodiments the methods make use of extension probes containing phosphorothiolate linkages and employ agents appropriate to cleave such linkages. In certain embodiments the methods make use of extension probes containing an abasic residue or a damaged base and employ agents appropriate to cleave linkages between a nucleoside and an abasic residue and / or agents appropriate to remove a damaged base from a nucleic acid. The invention provides methods of determining information about a sequence using at least two distinguishably labeled probe families. In certain embodiments the methods acquire less than 2 bits of information from each of a plurality of nucleotides in the template in each cycle. In certain embodiments the sequencing reactions are performed on templates attached to beads, which are immobilized in or on a semi-solid support. The invention further provides sets of labeled extension probes containing phosphorothiolate linkages or trigger residues that are suitable for use in the method. In addition, the invention includes performing multiple sequencing reactions on a single template by removing initializing oligonucleotides and extended strands and performing subsequent reactions using different initializing oligonucleotides. The invention further provides efficient methods for preparing templates, particularly for performing sequencing multiple different templates in parallel. The invention also provides methods for performing ligation and cleavage. The invention also provides new libraries of nucleic acid fragments containing paired tags, and methods of preparing microparticles having multiple different templates (e.g., containing paired tags) attached thereto and of sequencing the templates individually. The invention also provides automated sequencing systems, flow cells, image processing methods, and computer-readable media that store computer-executable instructions (e.g., to perform the image-processing methods) and / or sequence information. In certain embodiments the sequence information is stored in a database.

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.

An anode active material comprises graphite core particles, and a first coating layer and a second coating layer formed on the surface of the graphite core particles. The first coating layer comprises silicon microparticles and the second coating layer comprises carbon fiber.

The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

An object of the present invention is to provide a honeycomb filter for purifying exhaust gases having a structure in that, even when comparatively large sealing material layer is included therein, there is hardly any increase in the amount of organic components contained in exhaust gases to be discharged. The present invention provides a honeycomb filter for purifying exhaust gases, having a structure in that a sealing material layer is formed on a circumference of a columnar body made of porous ceramics, which has a number of through holes placed in parallel with one another in the length direction with wall portion interposed therebetween, and the wall portion which separate the through holes from each other functions as a filter for collecting particulates, wherein the rate Sα of an area occupied by the sealing material layers to the total area of a cross-section including the through holes in the direction perpendicular to the through holes is set to 0.5% or more, and the rate Vα of organic components to the honeycomb filter for purifying exhaust gases is set to 0.5% by weight or less.

A method of producing a fine particle of an organic pigment, containing the steps of: flowing a solution of an organic pigment dissolved in an alkaline or acidic aqueous medium, through a channel which provides a laminar flow; and changing a pH of the solution in the course of the laminar flow.

An intravitreal injection device for administering a pharmacological agent formulation to an intravitreal compartment of an eye, comprising (i) a nozzle member having an internal formulation chamber that is adapted to receive and contain the pharmacological agent formulation therein, (ii) a microneedle having a first end that is in communication with the nozzle member and a second ejection end, (iii) and piercing depth limiter means for limiting the penetration depth of the microneedle into the eye, the microneedle piercing depth limiter means including guide means for positioning the limiter means and guiding the microneedle.

The invention relates to vectors for delivering medicinal, nutritional, plant-protection or cosmetic active principles, these delivery particles being of small, controllable and adjustable particle size, which protect the active principle, and being biocompatible, biodegradable, non-immunogenic, stable and free of solvent. The particles do not denature the active principle and allow the active principle to be released. The microparticles of the invention are of a cohesive structure made of a physicochemically stable and integral composite gel which includes an oil such as coconut oil, an aqueous phase and a linear, non-crosslinked copolyamino acid of Leu / Glu type (random or diblock). The microparticles have a controllable and adjustable size of between 0.05 and 500 mum.

Disclosed is a controlled-release microparticle: including a matrix comprising a pharmacologically active component; and a controlled-release layer comprising a substance which forms a controlled-release stratum on the matrix. The disclosed controlled-release microparticle not only allows effective dual release control of a drug but can also exhibit outstanding dissolution characteristics even when a small amount of coating substance is used.

Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain antiproliferative agents, particularly a certain endothelin receptor inhibitor, are disclosed. The anti-restenotic endothelin receptor inhibitor is atrasentan, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the endothelin receptor inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-endothelin receptor inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one endothelin receptor inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.

The disclosure describes methods for producing bulk, particulate material that includes solid, generally ellipsoidal particles. Irregularly shaped feed particles with average particle sizes of up to 25 microns on a volume basis are dispersed in at least a portion of a combustible gas mixture by application of force and / or fluidizing agents. The combustible mixture with particles in suspension is then delivered, while controlling agglomeration or re-agglomeration of the particles, to at least one flame front. There, the mixture and suspended particles are uniformly distributed across the surface(s) of and passed through the flame front(s) with a high concentration of particles in the mixture. This flame front and the resultant flame(s) with suspended particles are located in at least one "wall free" zone. In such zone(s) the flame(s) may expand while the particles are maintained in dispersion and heated, with controlled and highly efficient application of heating energy. At least partial fusion occurs within at least the surfaces of the particles at high thermal efficiencies, while agglomeration of particles during fusion is inhibited.

The present invention is directed to an electrophoretic fluid which comprises uncharged or lightly charged neutral buoyancy particles. The resulting fluid can improve not only image stability but also contrast ratio of a display device, without significantly affecting the switching speed. The present invention is also directed to an electrophoretic display comprising display cells filled with the electrophoretic fluid.

A receptor medium with a sheet having an embossed imaging surface as one major surface thereof The receptor medium can receive jettable materials, which include inks, adhesives, biological fluids, chemical assay reagents, particulate dispersions, waxes, and combinations thereof. The embossed medium unexpectedly solves such common inkjet printing problems as feathering, banding, and mudcracking in inkjet printing systems by controlling how an inkjet drop contacts and dries on an inkjet receptor medium. Clear lines of demarcation between adjoining colors of a pigmented inkjet image graphic can be obtained, Methods of making and using the inkjet receptor medium are also disclosed.

The current invention, Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM) provides a significantly improved method for the production of nano and micro-particles with a narrow size distribution. The processes of the invention utilize the properties of supercritical fluids and also the principles of virbrational atomization to provide an efficient technique for the effective nanonization or micronization of particles. Like the SAS technique, SAS-EM, also uses a supercritical fluid as the antisolvent, but in the present invention the dispersion jet is deflected by a vibrating surface that atomizes the jet into fine droplets. The vibrating surface also generates a vibrational flow field within the supercritical phase that enhances mass transfer through increased mixing. Sizes of the particles obtained by this technique are easily controlled by changing the vibration intensity of the deflecting surface, which in turn is controlled by adjusting the power input to the vibration source. A major advantage of the SAS-EM technique is that it can be successfully used to obtain nanoparticles of materials that usually yield fibers or large crystals in SAS method. Microencapsulation via coprecipitation of two or more materials can also be achieved using the SAS-EM technique.

The current invention, Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM) provides a significantly improved method for the production of nano and micro-particles with a narrow size distribution. The processes of the invention utilize the properties of supercritical fluids and also the principles of virbrational atomization to provide an efficient technique for the effective nanonization or micronization of particles. Like the SAS technique, SAS-EM, also uses a supercritical fluid as the antisolvent, but in the present invention the dispersion jet is deflected by a vibrating surface that atomizes the jet into fine droplets. The vibrating surface also generates a vibrational flow field within the supercritical phase that enhances mass transfer through increased mixing. Sizes of the particles obtained by this technique are easily controlled by changing the vibration intensity of the deflecting surface, which in turn is controlled by adjusting the power input to the vibration source. A major advantage of the SAS-EM technique is that it can be successfully used to obtain nanoparticles of materials that usually yield fibers or large crystals in SAS method. Microencapsulation via coprecipitation of two or more materials can also be achieved using the SAS-EM technique.

The present invention is directed to an electrophoretic fluid comprising uncharged or lightly charged neutral buoyancy particles. The resulting fluid can improve not only image stability but also contrast ratio of a display device, without significantly affecting the switching speed. The present invention is also directed to an electrophoretic display comprising display cells filled with the electrophoretic fluid.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

A pharmaceutical dosage form such as a capsule capable of delivering therapeutic agents into the body in a time-controlled or position-controlled pulsatile release fashion, is composed of a multitude of multicoated particulates (beads, pellets, granules, etc.) made of one or more populations of beads. Each of these beads except an immediate release bead has at least two coated membrane barriers. One of the membrane barriers is composed of an enteric polymer while the second membrane barrier is composed of a mixture of water insoluble polymer and an enteric polymer. The composition and the thickness of the polymeric membrane barriers determine the lag time and duration of drug release from each of the bead populations. Optionally, an organic acid containing intermediate membrane may be applied for further modifying the lag time and / or the duration of drug release. The pulsatile delivery may comprise one or more pulses to provide a plasma concentration-time profile for a therapeutic agent, predicted based on both its pharmaco-kinetic and pharmaco-dynamic considerations and in vitro / in vivo correlations.

A method of revitalizing a fabric comprises directing a flow of air through a chamber while tumbling the fabric to dehydrate the fabric; removing particulates from the air flowing through the chamber; directing a treatment fluid into the chamber and onto the fabric; and tumbling the fabric while at least intermittently contacting the fabric with a low absorbency textured surface. In another embodiment, a method comprises placing the fabric in a chamber having a low absorbency textured surface; extracting fluid from the fabric to dehydrate the fabric; inserting treatment fluid into the chamber to apply the treatment fluid to the fabric; and extracting fluid from the fabric to dehydrate the fabric.

The invention relates to the immunoassay medical field, particularly provides a magnetic particle separation chemiluminescence immunoassay assay kit and a preparation method thereof used for detecting disease related markers. The kit of the invention comprises: 1) a calibrator; 2) magnetic particles which are coated with streptavidin; 3) disease related marker antibodies of enzyme markers and biotin markers; and 4) a chemiluminescence substrate. Further, the method for preparing the kit according to the invention includes the following steps: 1) pure raw materials are used to prepare the calibrator; 2) the streptavidin is used to coat the magnetic particles; 3) the mixed liquid of the enzyme and the biotin markers are prepared; 4) the calibrator, the chemiluminescence substrate as well as the mixed liquid of the enzyme and the biotin markers are packaged in a separated way; and 5) a finished product is packaged. The kit has the advantages of convenience, rapidness, sensitivity, stability, and the like.